Transcatheter aortic valve replacement: where will we be in 5 years?

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology

Background:

• Transcatheter aortic valve implantation (TAVI) has rapidly evolved into a key treatment for high-risk patients with aortic valve disease.
• Technological advancements in prosthesis design, delivery systems, imaging, and hybrid operating rooms are driving TAVI's progress.

Purpose of the Study:

• To review the current status and advancements in TAVI procedures.
• To evaluate the efficacy and safety of TAVI compared to standard medical therapy and conventional aortic valve replacement.

Main Methods:

• Analysis of data from the PARTNER randomized trial (cohort B).
• Review of large European registries for transapical and transfemoral TAVI.
• Assessment of evidence for CoreValve and SAPIEN valves, including prosthesis durability.

Main Results:

• The PARTNER trial demonstrated TAVI superiority over medical therapy in survival and function for high-risk patients.
• Transfemoral TAVI showed increased risks of stroke and vascular complications.
• European registries report improved procedural success and early survival rates for both transapical and transfemoral TAVI.
• The CoreValve and SAPIEN valves are leading devices, with published 3-year durability data for SAPIEN.

Conclusions:

• Growing evidence supports TAVI for high-risk, nonoperative aortic stenosis.
• Next-generation devices and technological improvements are enhancing TAVI reproducibility.
• TAVI represents a significant advancement in managing aortic valve disease.